Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study

Table 1 Binding of fibrinogen and expression of P-selectin as measured by flow cytometry.

Type of measurement	Activating agent	Reference values	ASA + Clopidogrel	ASA	Clopidogrel
Fibrinogen-binding	Control	1 (0–3.4)	2.3 ± 0.3***	5.0 ± 2.5^ns	2.4 ± 0.2***
	ADP 0.1	38 (17–59)	9.9 ± 1.3***	29.4 ± 3.6*	7.5 ± 1.4***
	ADP 0.6	74 (60–89)	32.5 ± 2.7***	62.1 ± 3.3**	22.9 ± 2.9***
	SFLLRN 5.3	76 (55–98)	28.8 ± 4.3***	48.5 ± 5.2***	20.2 ± 4.0***
P-selectin expression	Control	2 (0.9–3.1)	2.0 ± 0.2^ns	4.8 ± 0.9**	4.3 ± 0.6***
	ADP 0.6	26 (10–42)	7.6 ± 0.8***	24.8 ± 2.4^ns	10.9 ± 1.4***
	SFLLRN 5.3	88 (70–100)	33.0 ± 3.7***	55.4 ± 4.7***	34.4 ± 3.7***

Platelets from patients (n = 29) were activated in vitro with adenosine 5'-diphosphate (ADP; 0.1 and 0.6 μmol/L) or SFLLRN (5.3 μmol/L) followed by flow cytometric measurements of fibrinogen-binding or expression of P-selectin. Presented results are the mean-% of fibrinogen-binding and P-selectin expression ± SEM. Reference values (obtained earlier during routine analysis at the accredited Dept. of Clinical Chemistry at the University hospital in Linköping) are shown as mean with reference interval within parenthesis. Stars indicate significant differences for patients compared to reference values. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns = not significant.

ISSN: 1479-5876